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APPENDIX 1.
Calculation of the LAS involves the following patient
characteristics: age, body mass index, diabetes, functional
status, forced vital capacity (% predicted), systolic pulmo-
nary artery pressure, pulmonary capillary wedge pressure,
oxygen requirement, 6-minute walk distance less than
150 ft, continuous mechanical ventilation, partial pressure
of CO2, diagnosis, and creatinine.
The derivation of the LAS algorithm is explained in fur-
ther detail at the following UNOS website: http://www.
unos.org/docs/lung_allocation_score.pdf.Discussion
DrMichael Smith (Phoeniz, Ariz). Your work addresses an im-
portant question given the ongoing difficult problems with scarcity
of resources in transplantation principle, that is, the donor organs
themselves and the economic constraints on health care in general,
particularly in the arena of lung transplantation. The University of
Washington group and others (eg, the group in The Netherlands)
recently showed that among other common solid-organ trans-
plants, lung transplantation has been demonstrated to be the
most expensive, and this is mainly because of the higher cost of
postrecovery care. Many have suggested that although lung trans-
plantation can substantially improve quality of life, it has limited
cost-effectiveness. As a reaction to the difficult economic environ-
ment that we face today, some payers, including the Medicaid sys-
tem of my home state of Arizona, have determined that given the
limited survival advantages and poor cost-effectiveness, they will
no longer cover lung transplantation for their insured lives over the
age of 21 years. Given that we knowwe are trying to do the greatest
good for our patients with limited resources, how do we as trans-
plant physicians and surgeons act as good stewards of these limited
resources so that we can continue to provide care to our patients?
That is just a philosophical question.
The LAS has been an important step in the right direction in al-
lowing us to direct these limited resources more appropriately
compared with the old system of directing them simply by time
on the waiting list. Work such as yours helps to identify continued
limitations in the current system andmay help to point out facets of
the system that perhaps can be improved.
Given your findings, I have just a couple other comments and
questions. Your findings seem to identify some important limita-
tions of the current LAS system. One is that in approximately
90% of cases, our resources are going to patients who we are
not offering a survival benefit to and those in the lowest priority
group are actually better off without transplant from a survival
standpoint. At the other end of the spectrum, in the higher-1276 The Journal of Thoracic and Cardiovascular Surpriority groups, the LAS seems to over-advantage, if you will,
the sickness of the patient over the likelihood of an improved
survival after transplantation. As you mentioned, more long-
term data need to assessed to be certain of some of these con-
clusions, but given what you have at the present time, what
changes to the current LAS system would you recommend to
address these problems at either end of the LAS stratification
groups?
Dr Russo. Those are great questions. First, this analysis is not
meant to represent a criticism of the LAS. The LAS is a great
step forward over the previous system, which was essentially
based on waiting time alone. But under the current LAS system,
issues remain. The system should be designed to maximize the
net benefit of transplant However, medical urgency is weighted
more heavily than posttransplant survival. Therefore, patients in
the highest priority groups are sickest at the time of transplant
and thus, as expected, have the worst posttransplant outcomes.
This may prevent our maximizing the benefits from available or-
gans. In the future, I would support exploring the equal weighting
of expected survival on the waiting list and posttransplant survival
in future iterations of LAS. Second, as you point out, approxi-
mately 90% of the patients receiving transplants had lower-priority
LAS scores (<50). Concurrently, there were approximately 350
patients in the higher-priority groups who died on the waiting
list over the study period. You have to wonder why we’re perform-
ing transplantations in patients in the lower-priority group when
there are patients in the higher-priority group who die on the wait-
ing list. It may be because those patients were not appropriate for
transplant or for the donors who are available during their listing
time. However, I do not think this is the primary explanation.
Dr Smith. In terms of your methods, you looked at graft sur-
vival rather than patient survival after transplantation, and that
begs the question to me, do you think that re-transplantation plays
a significant role in improving survival in the groups of patients re-
ceiving transplants or offered transplantation, and could this bias
your data against a survival benefit of transplantation in the end?
Dr Russo. Graft survival is the standard measure of survival in
our analysis. In our opinion, graft survival has a number of advan-
tages over patient survival. First, given the critical scarcity of
organs available for transplantation, further expanding the benefit
of transplantation is predicated on improving the use of organs
available for transplantation. Analysis focusing on graft survival
rather than patient survival better addresses this important issue.
Moreover, if recipients receive multiple transplants during the
study period, survival obtained after retransplantation may be dou-
ble counted. That is, patient survival for recipients undergoing
transplantation twice during the study period is the sum of survival
of the initial transplant plus the survival after the second trans-
plant; patient survival after the second transplant will also be
included in analysis as a second, distinct observation, and thus is
counted twice. Finally, using patient survival in regression analysis
significantly confounds the model by allowing for a bailout strat-
egy of retransplant and introduces greater confounding by leaving
factors unaccounted for in the model, including the timing of the
retransplant, recipient clinical status at the time of the repeat trans-
plant, and characteristics of the donor involved in the retransplant.
Dr Smith. In the big picture, we cannot ignore the improve-
ments in quality of life that are offered to many of thesegery c May 2011
Russo et al Cardiothoracic Transplantationpatients because many would argue that lung transplantation
does allow many of our patients to become productive econom-
ically, both socially and economically, for their families and so-
ciety at large. I know that quality of life is beyond the scope of
this article, but perhaps you could comment on the relative im-
portance in these different patient priority groups, especially in
the absence of a demonstrated survival benefit. Along these
lines, how much should we weight quality of life in comparison
with survival advantage as we go forward in trying to improve
the LAS system?
Dr Russo. This is an excellent question. UNOS is a great re-
source because there are comprehensive and longitudinal survival
data. In outcome research, we frequently say that death is the ulti-
mate end point. But it is increasingly being recognized that quality
of life may be equally or more important. I think this is certainly
the case here.
Although the UNOS provides functional status data on recipi-
ents posttransplant, it is generally poorly populated, and there
are no longitudinal quality of life data on waiting list candidates.
Findings from this analysis highlight the importance of these
data, especially given the finding of limited survival benefit in
the lower-priority strata. It is possible that despite the limited sur-
vival benefit in some subgroups, there may be a significant benefit
in terms of quality-adjusted life years.
Therefore, a national effort should begin to measure quality of
life in candidates and recipients alike. Furthermore, future studies
should assess candidates’ preferences, including their willingness
to trade long-term survival for improved quality of life. This may
be particularly relevant to candidates in the lower-priority strata
who have longer survival on the waiting list, but poor quality of
life.
As stated in the Presidential Address, we need to be the stewards
of this effort. Given payors’ increasing resistance to reimburse for
costly therapies, if we cannot demonstrate a benefit from the
therapies that we offer, going forward, we may not be allowed to
provide them.
Dr Michael Mulligan (Seattle, Wash). Congratulations on
changing your title from when it was submitted to when it wasThe Journal of Thoracic and Carpresented. I think the title as it reads is a bit misleading, and for
those of us who sit on the pulmonary council, it is scary because
the LAS offers no guidance as to who should not receive a trans-
plant. Our charge over the next several years is to try to help refine
that, with help from our European colleagues.
I want to invite you to opine about 2 potential issues. One is if
you are assuming that limited survival benefit and a difficult to
quantitate quality of life benefit from performing transplantation
in a candidate with LAS less than 40, what would you propose?
Broader regional sharing akin to what we do for heart transplants,
where it is local 1A and 1B, and then it is farmed out before you
come back to a local status 2? And the other is because we double
weight waitlist mortality in calculating the LAS, what should we
do when the LAS starts to crest over 80? Because it is not a self-
correcting program, what would you propose for providing wider
more general usable user-friendly guidance for who should not
undergo transplantation?
Dr Russo. Those are great questions. First in terms of the organ
allocation issue, this is a question that our group is interested in ex-
ploring. We have preliminary data on this, which I did not present
here. However, if you look at the patients who undergo transplan-
tation with LAS less than 40, not surprisingly most of those organs
are procured locally, whereas candidates with LAS greater than 80,
organs were much more likely to be procured regionally or nation-
ally. This raises questions about broader organ sharing because
there be minimal benefit in performing transplantation in the
lower-priority group; in fact, there may be a negative benefit,
and again we have patients in the higher-priority groups dying
on the waitlist. Therefore, my bias is that, yes, there should be
broader organ sharing. However, the first step is to establish why
low-priority candidates are undergoing transplantation at such
a high rate while higher-priority candidates are dying on the
waitlist.
Regarding your second question, and I agree it is an important
issue, how should weweighmedical urgency versus expected post-
transplant survival? I cannot prove this, but I think that more
heavily weighing medical urgency prevents us from maximizing
benefit.diovascular Surgery c Volume 141, Number 5 1277
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